We present analysis of MACHO Alert 95-30, a dramatic gravitational microlensing event towards the Galactic bulge whose peak magnification departs significantly from the standard point-source microlensing model. Alert 95-30 was observed in real-time by the Global Microlensing Alert Network (GMAN), which obtained densely sampled photometric and spectroscopic data throughout the event. We interpret the light-curve "fine structure" as indicating transit of the lens across the extended face of the source star. This signifies resolution of a star several kpc distant.We find a lens angular impact parameter θ min /θ source = 0.715 ± 0.003. This information, along with the radius and distance of the source, provides an additional constraint on the lensing system. Spectroscopic and photometric data indicate the source is an M4 III star of radius 61 ± 12R ⊙ , located on the far side of the bulge at ∼ 9 kpc. We derive a lens angular velocity, relative to the source, of 21.5 ± 4.9 km s −1 kpc −1 , where the error is dominated by uncertainty in the source radius. Likelihood analysis yields a median lens mass of 0.67 +2.53 −0.46 M ⊙ , located with 80% probability in the Galactic bulge at a distance of 6.93 +1.56 −2.25 kpc. If the lens is a main-sequence star, we can include constraints on the lens luminosity. This modifies our estimates to M lens = 0.53 +0.52 −0.35 M ⊙ and D lens = 6.57 +0.99 −2.25 kpc. Spectra taken during the event show that the absorption line equivalent widths of Hα and the TiO bands near 6700Å vary, as predicted for microlensing of an extended source. This is most likely due to center-to-limb variation in the stellar spectral lines. The observed spectral changes further support our microlensing interpretation. These data demonstrate the feasibility of using microlensing limb crossings as a tool to probe stellar atmospheres directly.Subject headings: dark matter -gravitational lensing -stars: low-mass, brown dwarfsstars: late-type -stars: atmospheres Table 4. Photometry of the source star in MACHO 95-30Observed Extinction Dereddened Abs Mag, 8 kpc Abs Mag, 9 kpc V = 16.21 A V = 1.35 V 0 = 14.86 M V = +0.34 M V = +0.59 K = 9.98 A K = 0.15 K 0 = 9.83 M K = −4.69 M K = −4.45 V − R = 1.39 E(V − R) = 0.34 V − R 0 = 1.05 J − K = 1.12 E(J − K) = 0.23 J − K 0 = 0.89 H − K = 0.26 E(H − K) = 0.08 H − K 0 = 0.18 V − K = 6.23 E(V − K) = 1.21 V − K 0 = 5.03 Bolometric BC K = −2.7 ± 0.1 M bol = −2.0 M bol = −2.25

Purpose: Patients with mutations of epidermal growth factor receptor (EGFR) receive more benefit from EGFR-tyrosine kinase inhibitor treatment. However, usually such treatment is used to treat advanced lung cancer and only small biopsy samples are available for mutational analysis. We used immunohistochemistry to examine recently developed antibodies specific to major hotspot mutations of L858R and DEL E746-A750.Experimental Design: We used five series of lung cancers: 47 non-small cell lung cancers (NSCLC) to evaluate various types of EGFR mutations, a consecutive series of 238 NSCLCs to study the sensitivity and specificity, 11 NSCLCs with both EGFR mutation and amplification to examine the spatial distribution, 32 patients treated with gefitinib to compare clinical responses, and 15 NSCLCs to explore changes associated with acquired T790M mutation.Results: Each antibody specifically recognized the corresponding mutation but also recognized other types of mutations. Overall specificity and sensitivity were 96% and 47%, respectively. The positive reaction showed heterogeneous distribution that agreed with the expression of the total EGFR molecule, part of which was associated with gene amplification. A clinical response to gefitinib treatment correlated with the reaction, although one of the two patients with a positive reaction responded well despite having the wild-type EGFR. Acquired T790M mutation did not change the reaction to the antibodies.Conclusions: On some characteristics, the positive reaction to mutation-specific antibodies differs from the molecular EGFR mutation. Therefore, this study revealed that not all patients with EGFR mutations can be selected using these mutation-specific antibodies. Clin Cancer Res; 16(13); 3349-55. ©2010 AACR.

Comprehensive genetic panel testing generally requires that the analyzed tissues have a percent tumor nuclei (%TN) content of 20% or more to achieve assay performance comparable to the validated specifications. Pathologists play a crucial role in ensuring that the optimal results are achieved by accurately assigning %TN content of the available specimens and selecting the best material to submit for sequencing. This study addresses the issues in evaluating %

Our present study indicates that primary lymphomas arising in the nasal cavity are mostly of NK cell derivation. Our present study also suggests that a small number of cases are derived from NKT-cells.